# Device's design and clinical perspectives for resistant hypertension therapy

## TL;DR

This review discusses device-based treatments for resistant hypertension, highlighting their potential and challenges in clinical use.

## Contribution

The paper reviews recent innovations in device-based therapies for resistant hypertension and their clinical implications.

## Key findings

- Device-based therapies for resistant hypertension are supported by clinical studies and trials.
- Pharmacological non-adherence and sympathetic overactivity are key causes of resistant hypertension.
- Device design and larger RCTs are critical for determining their role in routine treatment.

## Abstract

Hypertension is the leading cause of death in the cardiovascular system. Indeed, untreated hypertension can affect one's general health, but medicine can help hypertensive people reduce their chance of developing high blood pressure. However, secondary hypertension remains an unresolved illness.

This review will go through the typical and unusual device-based therapies for resistant hypertension that have arisen in recent years. Further to that, the innovations developed in device-based RH treatment will be covered, as well as the research and studies assessing these novel technologies.

The innovative device-based techniques that target resistant hypertension provide a potential therapy that has been backed by a number of studies and clinical trials, whereas pharmacological non-adherence and increased sympathetic activity are recognized to be the primary causes of resistant hypertension. Nevertheless, some limitations will be critical for the future of these RH systems, with the device's design and larger RCTs playing a significant role in determining whether a position in routine treatment could be warranted.